# Sergey A. Kornilov, PhD

**Translational Science | Multi-Omics | Drug Discovery | Computational and Systems Biology | Machine Learning | A.I. | Behavioral Science | Language & Cognition | Psychometrics | Neurodevelopment | Neurodegeneration**

[![LinkedIn](https://img.shields.io/badge/LinkedIn-0077B5?style=flat&logo=linkedin&logoColor=white)](https://www.linkedin.com/in/sergey-kornilov/)
[![Email](https://img.shields.io/badge/Email-sergey@kornilov.bio-00C300?style=flat&logo=mail.ru&logoColor=white)](mailto:sergey@kornilov.bio)
[![Google Scholar](https://img.shields.io/badge/Google%20Scholar-4285F4?style=flat&logo=google-scholar&logoColor=white)](https://scholar.google.com/citations?user=xmwBz9EAAAAJ&hl=en)

---

## About

Translational scientist bridging computational approaches with biological understanding to accelerate therapeutic development. Currently guiding translational strategy for neurodegenerative diseases (ALS, Alzheimer's, PD/LBD, MS) with 15+ years experience in research and industry-facing R&D, including multi-omic integration, biomarker discovery, and clinical trial design.

**Current Focus:** Metabolic interventions in neurodegeneration | Multi-omic biomarker validation | Translational study design | A.I. in precision medicine

---

## Core Expertise

### ðŸ§¬ Multi-Omics & Computational Systems Biology
- **Platforms:** Olink PEA, SomaScan, Metabolon, IonS5, Illumina, 10x
- **Omics:**: Genomics (STRP, microarrays, WGS, WES), transcriptomics (bulk RNA-Seq, scRNA-Seq), proteomics, metabolomics
- **Analysis:** Bioinformatics, biostatistics,  simulation-based and patient-centered approaches (e.g., Latent Class Analysis)
- **Integration:** WGCNA, MEGENA, MOFA/MEFISTO, DIABLO, biclustering, network-based approaches

### ðŸ§  Clinical Research & Neuroscience
- **Methods:** Neurophysiology: EEG/ERP, (f)MRI, eye movements, digital biomarkers, observational and experimental study ndesign
- **Behavioral:** Psychometrics, assessment and test development, intelligence, decision making
- **Diseases:** ALS, Alzheimer's, Parkinson's/LBD, MS, neuropsychiatric and neurodevelopmental disorders, Metabolic Syndrome
- **Translation:** Biomarker validation, patient stratification, clinical trial design

### ðŸ’Š Drug Development
- **Discovery:** Target identification, MoA characterization, A.I.-enabled discovery (e.g., PandaOmics)
- **Clinical:** RCT & trial design, biomarker strategy, regulatory documentation, CDISC foundational standards
- **Analytics:** Power analysis, biostatistics, machine learning, causal inference, longitudinal modeling, RWE
- **Indication prioritization** 


### ðŸ’» Technical Stack
`R (Expert)` `Python` `SQL` `AWS/GCP` `Docker` `Shiny` `Statistical Modeling` `Machine Learning`

---

## Current Projects

ðŸ”¬ **Metabolic Therapy Platform** - Guiding translational strategy for neurodegenerative applications  
ðŸ“Š **Multi-Omic Biomarker Suite** - Developing integrated biomarkers for disease progression  
ðŸ¤– **ML Pipeline Development** - Building scalable analysis pipelines for clinical data

---

## Selected Publications

ðŸ“„ **65+ peer-reviewed publications** | [Full list on Google Scholar](https://scholar.google.com/citations?user=xmwBz9EAAAAJ&hl=en)

- Kornilov, S., Price, N., Gelinas, R., ... & Magis, A. (2024). Multi-Omic characterization of the effects of Ocrelizumab in patients with relapsing-remitting multiple sclerosis. Journal of the Neurological Sciences, 467, 123303, 10.1016/j.jns.2024.123303
- Heath, L. Earls, J., Magis, A., Kornilov, S., ... Price, N. (2022). Manifestations of Alzheimer's disease genetic risk in the blood are evident in a multiomic analysis in healthy adults aged 18 to 90. Scientific Reports, 12(6117), 10.1038/s41598-022-09825-2
- Kornilov, S., Lucas, ... & Magis, A. (2020). Plasma levels of soluble ACE2 are associated with sex, Metabolic Syndrome, and its biomarkers in a large cohort, pointing to a possible mechanism for increased severity in COVID-19. Critical Care, 24, 452, 10.1186/s13054-020-03141-9.
- Kornilov, S., Zhukova, M., ... & Grigorenko, E.L. (2018). Language Outcomes in Adults with a History of Institutionalization: Behavioral and Neurophysiological Characterization. Scientific Reports, 9, 10.1038/s41598-019-40007-9
- Kornilov, S., Rakhlin, N., ... & Grigorenko, E.L. (2016). Genome-Wide Association and Exome Sequencing Study of Language Disorder in an Isolated Population. Pediatrics, 137(4), 10.1542/peds.2015-2469
- Kornilov, S., Tan, M., Aljughaiman, A., Naumova, O.Y., & Grigorenko, E.L. (2019). Genome-Wide Homozygosity Mapping Reveals Genes Associated With Cognitive Ability in Children From Saudi Arabia. Frontiers in Genetics, 10, 888. 10.3389/fgene.2019.00888
  
---

## Professional Background

**Founder & Translational Scientist** | Biostochastics LLC (2024-Present)  
**Senior Research Scientist** | Institute for Systems Biology (2019-2024)  
**Statistical Geneticist** | Arivale Inc (2018-2019)  
**Research Assistant Professor** | University of Houston (2017-2018)

**Education:** PhD Experimental Psychology (UConn) | PhD Educational Psychology (Moscow State University)  
**Training:** Duncan Scholar, Baylor College of Medicine | Post-doc, Yale School of Medicine
**Awards:** Outstanding Doctoral Dissertation in Developmental Science (Society for Research in Child Development), GoldenHelix Award for Best Research, Isabelle Libermann award. 

---

## Let's Collaborate

Open to partnerships in:
- Neurodegenerative disease therapeutics
- Metabolic and multi-omic studies
- Multi-omic biomarker discovery
- Clinical trial design with novel endpoints
- Computational tools for drug development

ðŸ“§ **Contact:** sergey@kornilov.bio | [LinkedIn](https://www.linkedin.com/in/sergey-kornilov/)

